Article
Successful Treatment of Intracranial Glioblastoma Xenografts With a Monoamine Oxidase B-Activated Pro-Drug.
EBioMedicine - 1 Sept 2015
Sharpe Martyn A, Livingston Andrew D, Gist Taylor L, Ghosh Pardip, Han Junyan, Baskin David S
Abstract excerpt
The last major advance in the treatment of glioblastoma multiforme (GBM) was the introduction of temozolomide in 1999. Treatment with temozolomide following surgical debulking extends survival rate compared to radiotherapy and debulking alone. However, virtually all glioblastoma patients experience disease progression within 7 to 10 months. Although many salvage treatments, including bevacizumab, rechallenge with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.